



(51) International Patent Classification:

A61K 38/48 (2006.01) *C07K 14/81* (2006.01)
A61K 38/16 (2006.01) *A61K 38/49* (2006.01)
C12N 9/64 (2006.01)

(21) International Application Number:

PCT/US2022/011873

(22) International Filing Date:

10 January 2022 (10.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/135,496 08 January 2021 (08.01.2021) US
 63/221,108 13 July 2021 (13.07.2021) US

(71) Applicant: **CATALYST BIOSCIENCES, INC.** [US/US];
 611 Gateway Boulevard, Suite 710, South San Francisco,
 California 94080 (US).

(72) Inventors: **POPKOV, Mikhail**; c/o Catalyst Biosciences,
 Inc., 611 Gateway Boulevard, Suite 710, South San Francisco,
 California 94080 (US). **SOROS, Vanessa**; c/o Catalyst
 Biosciences, Inc., 611 Gateway Boulevard, Suite 710, South
 San Francisco, California 94080 (US). **LE MOAN, Nat-**

acha; c/o Catalyst Biosciences, Inc., 611 Gateway Boulevard,
 Suite 710, South San Francisco, California 94080
 (US). **BLOUSE, Grant E.**; c/o Catalyst Biosciences, Inc.,
 611 Gateway Boulevard, Suite 710, South San Francisco,
 California 94080 (US). **MYLES, Timothy**; c/o Catalyst
 Biosciences, Inc., 611 Gateway Boulevard, Suite 710, South
 San Francisco, California 94080 (US).


(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylv-
 ania Ave., Suite 700, Washington, District of Columbia
 20004 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
 NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
 SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,

(54) Title: FACTOR B PROTEASES

FIG. 7B FB cleavage assay with KLK5



(57) Abstract: Provided herein are engineered proteases of the S1A family that are specific for, and capable of, cleaving Factor B. Also provided herein are methods of making and using such engineered proteases. The engineered proteases provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system by reducing complement activation through cleavage and inactivation of Factor B.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*